Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanoma.

Lineage dedifferentiation toward a mesenchymal-like state displaying myofibroblast and fibrotic features is a common mechanism of adaptive and acquired resistance to targeted therapy in melanoma. Here, we show that the anti-fibrotic drug nintedanib is active to normalize the fibrous ECM network, enhance the efficacy of MAPK-targeted therapy, and delay tumor relapse in a preclinical model of melanoma. Acquisition of this resistant phenotype and its reversion by nintedanib pointed to miR-143/-145 pro-fibrotic cluster as a driver of this mesenchymal-like phenotype. Upregulation of the miR-143/-145 cluster under BRAFi/MAPKi therapy was observed in melanoma cells in vitro and in vivo and was associated with an invasive/undifferentiated profile. The 2 mature miRNAs generated from this cluster, miR-143-3p and miR-145-5p, collaborated to mediate transition toward a drug-resistant undifferentiated mesenchymal-like state by targeting Fascin actin-bundling protein 1 (FSCN1), modulating the dynamic crosstalk between the actin cytoskeleton and the ECM through the regulation of focal adhesion dynamics and mechanotransduction pathways. Our study brings insights into a novel miRNA-mediated regulatory network that contributes to non-genetic adaptive drug resistance and provides proof of principle that preventing MAPKi-induced pro-fibrotic stromal response is a viable therapeutic opportunity for patients on targeted therapy.

SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.

BACKGROUND & AIMS: Spleen tyrosine kinase (SYK) signaling pathway regulates critical processes in innate immunity, but its role in parenchymal cells remains elusive in chronic liver diseases. We investigate the relative contribution of SYK and its substrate c-Abl Src homology 3 domain-binding protein-2 (3BP2) in both myeloid cells and hepatocytes in the onset of metabolic steatohepatitis. METHODS: Hepatic SYK-3BP2 pathway was evaluated in mouse models of metabolic-associated fatty liver diseases (MAFLD) and in obese patients with biopsy-proven MAFLD (n = 33). Its role in liver complications was evaluated in Sh3bp2 KO and myeloid-specific Syk KO mice challenged with methionine and choline deficient diet and in homozygous Sh3bp2KI/KI mice with and without SYK expression in myeloid cells. RESULTS: Here we report that hepatic expression of 3BP2 and SYK correlated with metabolic steatohepatitis severity in mice. 3BP2 deficiency and SYK deletion in myeloid cells mediated the same protective effects on liver inflammation, injury, and fibrosis priming upon diet-induced steatohepatitis. In primary hepatocytes, the targeting of 3BP2 or SYK strongly decreased the lipopolysaccharide-mediated inflammatory mediator expression and 3BP2-regulated SYK expression. In homozygous Sh3bp2KI/KI mice, the chronic inflammation mediated by the proteasome-resistant 3BP2 mutant promoted severe hepatitis and liver fibrosis with augmented liver SYK expression. In these mice, the deletion of SYK in myeloid cells was sufficient to prevent these liver lesions. The hepatic expression of SYK is also up-regulated with metabolic steatohepatitis and correlates with liver macrophages in biopsy-proven MAFLD patients. CONCLUSIONS: Collectively, these data suggest an important role for the SYK-3BP2 pathway in the pathogenesis of chronic liver inflammatory diseases and highlight its targeting in hepatocytes and myeloid cells as a potential strategy to treat metabolic steatohepatitis.

Development of Quercetin Based Nanodispersions.

Polyphenols are a large group of structurally diverse natural products, including flavonoids. One of the most bioactive compounds of this class is the flavonol quercetin, a recognized antioxidant. Despite several studies were carried out aiming to develop nanoformulations with secondary metabolites, to our knowledge, quercetin was not used as raw material for nanodispersion production without coating polymers. This type of nanosize formulation is often prepared using organic solvents and quercetin nanodispersions were prepared by emulsification evaporation technique, using 1(6).2(2) experimental factorial design, ("surfactant type" evaluated at 6 levels, "surfactant amount" and "stirring speed" evaluated at 2 levels). Variance analysis, after one day of nanodispersions preparation, revealed that only the surfactant type was statistically significant on particle size, while none of factors presented statistically significant effect on polydispersity index. Variance analysis after seven days of nanodispersions preparation revealed that either surfactant type and surfactant amount presented significant effect on particle size, while only surfactant type influenced polydispersity index. Some nanodispersions presented small diameter and narrow size distribution, suggesting potential stability of these systems. Special attention was given to nanodispersion prepared with 3 % (w/w) of polyethylene glycol 400 monooleate (expressed as function of surfactant concentration at aqueous phase). It presented mean droplet size of 129.4 ± 0.5 nm and polydispersity index of 0.173 ± 0.018, after 7 days of preparation. Low polydispersity index indicates a high homogeneity concerning particle size distribution and suggests stability of the system. Moreover, absence of coating polymers and utilization of a low energy method would be an advantage in terms of reducing costs for industrial application, without any nanosize impairment.